{"id":407402,"date":"2021-01-04T08:03:38","date_gmt":"2021-01-04T13:03:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407402"},"modified":"2021-01-04T08:03:38","modified_gmt":"2021-01-04T13:03:38","slug":"soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/","title":{"rendered":"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., Jan.  04, 2021  (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that\u00a0management  will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.<\/p>\n<p>The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gsEREt6Kv-DcpoKJeFzvp9JE1A50q5DDbQupieaI_6ZAjXc_OlRXGMOhb2mh3-ZZBcUWZwim5Ot9ah405phmcA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.soleno.life<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Soleno Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program. For more information, please visit www.soleno.life.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors, LLC<br \/>212-915-2578<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b20b8292-0029-4334-9d80-91ccb23e8f2e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that\u00a0management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company\u2019s website at www.soleno.life. About\u00a0Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407402","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that\u00a0management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company\u2019s website at www.soleno.life. About\u00a0Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical &hellip; Continue reading &quot;Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T13:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference\",\"datePublished\":\"2021-01-04T13:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/\"},\"wordCount\":151,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/\",\"name\":\"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==\",\"datePublished\":\"2021-01-04T13:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/","og_locale":"en_US","og_type":"article","og_title":"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that\u00a0management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company\u2019s website at www.soleno.life. About\u00a0Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical &hellip; Continue reading \"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T13:03:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference","datePublished":"2021-01-04T13:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/"},"wordCount":151,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/","name":"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==","datePublished":"2021-01-04T13:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTAxNSMzODk4ODgyIzUwMDA3Mjk5OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407402"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}